IVVD is the Nasdaq stock ticker symbol for Invivyd Inc., a clinical-stage biopharmaceutical enterprise focused on protecting vulnerable populations from severe viral infectious diseases. The company specializes in leveraging advanced engineering platforms to discover, develop, and commercialize novel monoclonal antibody therapies designed to provide rapid and durable passive immunity. Their primary research initiatives target fast-mutating viral pathogens, aiming to offer reliable pre-exposure prophylaxis alternatives for immunocompromised individuals who cannot mount adequate responses to conventional vaccines.